Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. Co. has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats technology and it continues to expand its capabilities. Co. is developing in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, ex vivo gene-edited cell medicines, in which cells collected from a patient are edited with Co.'s technology and then administered back to that same patient, and cellular therapy medicines. We show 33 historical shares outstanding datapoints in our EDIT shares outstanding history coverage, used to compute EDIT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EDIT market cap history over the course of time is important for investors
interested in comparing EDIT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EDIT versus a peer is one thing; comparing
EDIT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EDIT can fluctuate over the course of history.
With this page we aim to empower investors researching EDIT by allowing them to research the EDIT market cap history. |
Free EDIT Email Alerts:
Video: The Importance of Market Cap
